Top
image credit: Freepik

New clinical trial shows combination of two innovative precision medicines could treat multiple cancers

September 15, 2020

Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows.

It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together with a promising new medicine, called capivasertib.

The researchers used the drug combination to target two fundamental weaknesses in cancer at the same time – a damaged system for repairing DNA, and ‘addiction’ to a molecule called AKT which fuels tumour growth.

Read More on The Medical News